After conducting network pharmacology analyses and reviewing the relevant literature, the TLR4/NF-κB pathway was further validated in animal studies to investigate the mechanism of APS treatment in epileptogenesis and its comorbidities. Here, NFKB1 is linked to autoimmune polyendocrinopathy.